Skip to main content

Drug Interactions between apixaban and Dexamethasone Intensol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

dexAMETHasone apixaban

Applies to: Dexamethasone Intensol (dexamethasone) and apixaban

Theoretically, coadministration with inducers of CYP450 3A4 and/or P-glycoprotein (P-gp) may decrease the plasma concentrations of apixaban, which is a substrate of both the isoenzyme and the efflux transporter. When apixaban was coadministered with 600 mg/day of rifampin, a dual P-gp and potent CYP450 3A4 inducer, mean apixaban peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 42% and 54%, respectively. No data are available for use with other, less potent CYP450 3A4 and/or P-gp inducers.

References (6)
  1. (2012) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Canada Inc
  2. (2021) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb, SUPPL-34
  3. (2024) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Pharmaceuticals Ltd
  4. (2025) "Product Information. Apixaban (apixaban)." Teva UK Ltd
  5. (2024) "Product Information. Eliquis (apixaban)." Bristol-Myers Squibb Australia Pty Ltd
  6. (2022) "Product Information. ACH-Apixaban (apixaban)." Accord Healthcare Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer